Plan to Invest 4 Trillion Won to Expand Facilities in South Korea
South Korean biopharmaceutical giant Celltrion announced an investment of 4 trillion won to expand its production base in South Korea. This move is in response to the increasing global demand for the company's biosimilars and new drugs. As the international market accelerates, the company is seeking to establish a more comprehensive and resilient global supply system over the next decade.
Celltrion emphasized that this expansion is a core component of the company's global capacity strategy, although a specific timeline for the investment has not been disclosed. Industry experts speculate that the expansion may include large-scale production equipment, automated facilities, and quality control system upgrades to meet the rising export volumes in the future.
Formation of the US-Korea "Dual Hub Strategy"
In September, Celltrion announced the acquisition of Eli Lilly's US plant for 460 billion won, with the transaction expected to close within the year. The company further stated on Wednesday that the US plant will mainly serve the local market, while the South Korean production base will meet global demands outside the US, ensuring regional supply stability.
The company's management noted that the US capacity layout not only allows for more flexible service to the North American market but also directly avoids potential tariff and trade barrier risks. Previously, Celltrion had shipped a two-year inventory to the US in advance and expanded partnerships with local CMOs. The acquisition of the plant now allows for a more complete localized production capability.
According to the company's plans, the total investment related to the US plant will reach 1.4 trillion won, including acquisition costs and future expansion funds.
Rapid Expansion of Global Product Portfolio
In recent years, Celltrion has actively expanded its biosimilar pipeline, increasing its commercialized products from six to eleven. The company aims to expand the number of products to 18 by 2030 and to 41 by 2038.
Its flagship original drug, Zymfentra, is currently sold in the US for treating various autoimmune diseases. In Europe and other regions, the product is marketed as the biosimilar Remsima SC and has established a solid market foundation.
Industry analysts believe that at a time when the global biopharmaceutical supply chain is highly tense and demand continues to grow, Celltrion's accelerated expansion will help consolidate its competitive position in the international market and enhance long-term growth prospects.
Building a Global One-Stop Supply Chain
Celltrion stated that the introduction of new factories will further strengthen the company's global one-stop supply system, enabling the full process from drug production to commercialization to be completed at the two core bases in the US and South Korea. This move is expected to enhance the speed and stability of supply to various markets while reducing uncertainties in cross-border production processes.
As the investment layout continues to expand, Celltrion is advancing towards becoming a "globalized pharmaceutical company" at a higher level. The market generally expects the company to further increase its market share in North America, Asia, and Europe in the coming years and to accelerate the dual-line development of biosimilars and innovative drugs.
